AI Payer Avatars for Market Access Workshops
How can market access teams practise payer value stories?
An AI payer avatar is a conversational simulation of a payer, such as a health economist or a budget holder. A market access team pitches its value story to the avatar and gets a scored response before anyone sits down with the real audience.
Teams already run value story workshops and mock payer negotiations. Those sessions work. The constraint is the person across the table. A former HTA assessor can sit with one group at a time, so a workshop of 20 people produces a lot of listening and very little practice. Avatars give every group a payer who will interrupt them. How sharp that payer is depends on the evidence pack, and on the review the client does before the day.
Why is it hard to rehearse a payer value story?
It is hard because the people best placed to challenge a value story are the people a team has least access to. Real payers and former HTA assessors are scarce, and a workshop can usually borrow one of them for a single slot. Rehearsal then becomes colleagues pitching to colleagues. They share the same assumptions, so a weak claim often survives the room.
In a group of 20, that external expert might hear four pitches. The other groups watch, take notes, and leave without having said the story out loud under pressure.
The feedback is also difficult to line up. If one expert questions group A and a different expert questions group B, the room has two opinions and no shared scale. Nobody can point to the narrative that was actually stronger.
Each payer in the room is listening for something different. A clinician on an appraisal committee wants to know whether the endpoint matters to patients. A budget holder wants to know what comes out of the budget to pay for the product. A health economist wants the assumption that would flip the result if it moved. One friendly sounding board rarely runs a story through all of those tests.
How does an AI payer avatar workshop work?
A half-day workshop of around 20 people gives every group two sessions with AI payers: a coaching session, then a scored evaluation. For a 3.5 hour face-to-face day, the running order is below. Groups join in a browser. There is nothing to install, and a TrainBox facilitator is in the room to run the rotations. The conversations sit on the AI roleplay platform, with payer personas in place of the usual HCP.
New evidence is presented
The team walks through the data the value story has to carry. That might be a new trial readout, or a real-world evidence package the affiliates have been waiting on. Everyone drafts from the same pack, so later scores can be compared.
Groups draft a value narrative
People split into groups of about four and build the payer story from that evidence. Four is small enough that nobody can sit out the drafting.
Coaching session
Each group gets about 30 minutes with the avatars. The avatars ask the questions a payer in that market would ask, and they stay on a weak claim instead of moving on to be polite. The useful output is the list of places the story gave way.
The narrative gets rewritten
Groups rework the story from those challenges. The movement between this draft and the final pitch is what the scores later pick up.
Evaluation session
Each group gets about 30 minutes to deliver the final value pitch. The platform scores it against the agreed rubric, either live or from an uploaded pitch document.
Debrief
Facilitators name the strongest value story and the reasons for it, in front of the whole room. The other groups can see which claim held up once a payer refused the first answer.
We run a pilot at least two weeks before the workshop. The client team uses the avatars, marks anything that sounds wrong, and we change it while there is still time.
Which payer archetypes should the avatars cover?
Use the payer types who will actually be in the appraisal. A value story has to survive more than one line of questioning, and each line fails a weak pitch in a different place. We build a clinical assessor, a budget holder and a health economist from the client's own payer insight and approved evidence. A generic "tough payer" who could be sitting in any country is little help to a team preparing a specific submission.
Clinical assessor
The pressure here is unmet need, the comparator and the endpoints, and whether the benefit means something to a patient. A thin pitch usually fails on: "Why should I believe this outcome matters more than the current standard of care?"
Budget holder
This conversation is about affordability, how large the eligible population really is, likely uptake, and what the product does to the rest of the budget. Expect some version of: "What does this cost my budget in years one to three, and what do I stop paying for?"
Health economist
They will go after value for money: the modelling assumptions, the uncertainty, and the threshold the HTA body actually applies. The model is in trouble if nobody can answer: "Which assumption in your model would change the answer if it were wrong?"
The same archetypes can be rebuilt for a national process. NICE in England, the G-BA in Germany and HAS in France do not ask the same economic question, and the avatar should follow the body the team is preparing for.
How are value pitches scored?
Pitches are scored against a rubric the client agrees before the workshop. The platform shows the reason for every score, and the people in the room decide what to do with it.
Can a payer repeat the core value claim in one sentence?
The claim is ready when a payer can say it back in one sentence.
Is every claim tied to approved data, with the right comparator?
A strong endpoint against the wrong comparator still fails this test.
Does the pitch answer each archetype?
A story that satisfies the clinician and never deals with the budget is unfinished. The rubric checks the clinical question, the budget question and the cost-effectiveness question separately, so a gap in one of them is visible.
Does the team deal with uncertainty when asked?
Assessors tend to trust a limitation that is named and bounded. The rubric marks whether the group handles the weak point, or steps around it.
What happened when the avatar pushed back?
Objection handling is scored from what the group says once the avatar pushes back. A clean document can still come apart when the avatar refuses the first answer and asks again.
The room sees the rubric, the score and the reasons side by side. The debrief then has something specific to discuss: the claim that accounted for the difference in score.
How do you stop the avatars inventing data?
You ground them in the client's approved evidence, and the client's own team reviews every persona before it is used. An avatar that invents a comparator, or cites a figure that is not in the pack, makes the session worthless. Most of the build time goes on this.
The knowledge base is the evidence pack being presented on the day, plus the payer insight the client already holds. At the pilot, the market access team reads what each archetype knows and how it behaves, then asks for changes. The client also owns the rubric. "A strong pitch" means what they mean by it.
TrainBox is independently certified to ISO 27001:2022 and ISO 9001:2015, and processes data within the EU. We send security and compliance documentation to IT early in the setup, so a security review is finished before the workshop date is at risk.
What should a payer workshop measure?
A workshop should leave evidence that the value story improved, and a record of the holes that are still open.
Each group has a rubric score on the first draft and another on the final pitch, plus a short confidence rating from before the session and after it. The output teams use most is the set of objections nobody had prepared. Those challenges show where the story is exposed, and they usually become the work for the fortnight afterwards. It is also worth counting which archetype caught a weak argument most often. If the health economist keeps landing hits and the clinician does not, the narrative is ready for one audience and thin for the other.
Transcripts, scores and those objections go into a written report about a week after the session.
Why does payer rehearsal matter more under the EU HTA Regulation?
It matters because joint clinical assessment has started, and a value story now has to hold up earlier, in a form national payers will read.
Article 7 of Regulation (EU) 2021/2282 sets the dates. From 12 January 2025, joint clinical assessment covers medicines whose application declares a new active substance for the treatment of cancer, and products regulated as advanced therapy medicinal products. From 13 January 2028 it extends to orphan medicines. From 13 January 2030 it covers the remaining medicines in scope. National pricing and reimbursement still happen country by country, once that joint report exists.
The rehearsal load goes up with the scope. The same story has to survive a joint assessment and then a national payer who has already read it. Teams who can put every group through a realistic payer, more than once, have already heard the awkward question.
If a workshop or a national submission is already on the calendar, we can build payer avatars from the evidence pack and run the session with the team. Book a 20-minute call and we will walk through a live demo with a sample payer archetype.
Sources
The joint clinical assessment dates above are Article 7(2) of Regulation (EU) 2021/2282 on health technology assessment, as published on EUR-Lex.